Tags

Condition: Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms, Metastatic Renal Cell Carcinoma, Ovarian Clear Cell Carcinoma

Intervention:

• Drug: CDX-014

Purpose: This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02837991

Sponsor: Celldex Therapeutics

Primary Outcome Measures:

• Measure: Dose Escalation - Determine Maximum Tolerated Dose (MTD)
• Time Frame: Within 21 days after first dose.
• Safety Issue:
• Measure: Cohort Expansion - Assess Objective Response Rate (ORR)
• Time Frame: Evaluated every 6-9 weeks following treatment initiation until treatment is discontinued or disease progression, up to 5 years.
• Safety Issue:

Estimated Enrollment: 125

Study Start Date: June 2016

Phase: Phase 1

Eligibility:

• Age: minimum 18 Years maximum N/A
• Gender: All

Inclusion Criteria:

1. Histologically confirmed diagnosis of advanced or metastatic clear cell or papillary renal cell carcinoma or histologically confirmed clear cell ovarian carcinoma.
2. For RCC, at least two prior anticancer regimens (one must be a VEGF-targeted TKI), or are otherwise inappropriate candidates for all approved therapies. For OCCC, at least one line of prior therapy with a platinum and taxane regimen.
3. Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
4. Measureable (target) disease.
5. Must have available tumor tissue for TIM-1 expression testing
6. Life expectancy ≥ 3 months
7. If of childbearing potential (male or female), agrees to use effective contraception during study treatment and for at least 6 months following last treatment dose.

Exclusion Criteria:

1. Prior therapy containing MMAE
2. Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within 3 weeks of study treatment for OCCC
3. Tyrosine kinase inhibitor (TKI) therapy within 2 weeks or at least 5 half-lives (whichever is longer) prior to planned start of study treatment.
4. Monoclonal antibody therapy within 4 weeks prior to the planned start of study treatment.
5. Radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).
6. Major surgery or significant traumatic injury within 4 weeks prior to study entry.
7. Use of other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study treatment.
8. Concurrent severe and/or uncontrolled medical conditions (uncontrolled diabetes or infection), known infection with HIV, Hepatitis B or Hepatitis C.
9. Brain metastases, unless previously treated and asymptomatic and not progressive for 2 months.
10. Significant cardiovascular disease (including congestive heart failure).
11. Other malignancy except for treated and cured basal or squamous cell skin cancer, cured in situ cancers, or other cancer from which the patient has been disease-free for ≥ 3 years.
12. Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
13. Chronic use of systemic corticosteroid above an accepted physiologic dose (5mg per day of prednisone or equivalent) within 7 days of enrollment except when used as premedication

Contact:

• Celldex Therapeutics

Locations:

• HonorHealth Research Institute
• Scottsdale Arizona 85258 United States

• USC/Norris Comprehensive Cancer Center
• Los Angeles California 90033 United States

• Dana Farber Cancer Institute
• Boston Massachusetts 02215 United States

• Roswell Park Cancer Institute
• Buffalo New York 14263 United States

• Huntsman Cancer Institute
• Salt Lake City Utah 84112 United States

View trial on ClinicalTrials.gov